Coherus BioSciences (CHRS) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.67 +7.05%
Revenue Growth %: +40.6%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: +40.6%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Starts Holley (HLLY) at Buy
- Nasdaq moves to delist Pitanium Limited securities by July 16
- Lockheed Martin wins $607M in defense contracts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
